The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study.
Parkinson disease
artificial intelligence
self-management
telemedicine
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
26 Sep 2022
26 Sep 2022
Historique:
received:
15
06
2022
accepted:
30
06
2022
revised:
30
06
2022
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Nonmotor symptoms of Parkinson disease are a major factor of disease burden but are often underreported in clinical appointments. A digital tool has been developed to support the monitoring and management of nonmotor symptoms. The aim of this study is to establish evidence of the impact of the system on patient confidence, knowledge, and skills for self-management of nonmotor symptoms, symptom burden, and quality of life of people with Parkinson and their care partners. It will also evaluate the usability, acceptability, and potential for adoption of the system for people with Parkinson, care partners, and health care professionals. A mixed methods implementation and feasibility study based on the nonadoption, abandonment, scale-up, spread, and sustainability framework will be conducted with 60 person with Parkinson-care partner dyads and their associated health care professionals. Participants will be recruited from outpatient clinics at the University Hospitals Plymouth NHS Trust Parkinson service. The primary outcome, patient activation, will be measured over the 12-month intervention period; secondary outcomes include the system's impact on health and well-being outcomes, safety, usability, acceptability, engagement, and costs. Semistructured interviews with a subset of participants will gather a more in-depth understanding of user perspectives and experiences with the system. Repeated measures analysis of variance will analyze change over time and thematic analysis will be conducted on qualitative data. The study was peer reviewed by the Parkinson's UK Non-Drug Approaches grant board and is pending ethical approval. The study won funding in August 2021; data collection is expected to begin in December 2022. The study's success criteria will be affirming evidence regarding the system's feasibility, usability and acceptability, no serious safety risks identified, and an observed positive impact on patient activation. Results will be disseminated in academic peer-reviewed journals and in platforms and formats that are accessible to the general public, guided by patient and public collaborators. ClinicalTrials.gov NCT05414071; https://clinicaltrials.gov/ct2/show/NCT05414071. PRR1-10.2196/40317.
Sections du résumé
BACKGROUND
BACKGROUND
Nonmotor symptoms of Parkinson disease are a major factor of disease burden but are often underreported in clinical appointments. A digital tool has been developed to support the monitoring and management of nonmotor symptoms.
OBJECTIVE
OBJECTIVE
The aim of this study is to establish evidence of the impact of the system on patient confidence, knowledge, and skills for self-management of nonmotor symptoms, symptom burden, and quality of life of people with Parkinson and their care partners. It will also evaluate the usability, acceptability, and potential for adoption of the system for people with Parkinson, care partners, and health care professionals.
METHODS
METHODS
A mixed methods implementation and feasibility study based on the nonadoption, abandonment, scale-up, spread, and sustainability framework will be conducted with 60 person with Parkinson-care partner dyads and their associated health care professionals. Participants will be recruited from outpatient clinics at the University Hospitals Plymouth NHS Trust Parkinson service. The primary outcome, patient activation, will be measured over the 12-month intervention period; secondary outcomes include the system's impact on health and well-being outcomes, safety, usability, acceptability, engagement, and costs. Semistructured interviews with a subset of participants will gather a more in-depth understanding of user perspectives and experiences with the system. Repeated measures analysis of variance will analyze change over time and thematic analysis will be conducted on qualitative data. The study was peer reviewed by the Parkinson's UK Non-Drug Approaches grant board and is pending ethical approval.
RESULTS
RESULTS
The study won funding in August 2021; data collection is expected to begin in December 2022.
CONCLUSIONS
CONCLUSIONS
The study's success criteria will be affirming evidence regarding the system's feasibility, usability and acceptability, no serious safety risks identified, and an observed positive impact on patient activation. Results will be disseminated in academic peer-reviewed journals and in platforms and formats that are accessible to the general public, guided by patient and public collaborators.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05414071; https://clinicaltrials.gov/ct2/show/NCT05414071.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
PRR1-10.2196/40317.
Identifiants
pubmed: 36155396
pii: v11i9e40317
doi: 10.2196/40317
pmc: PMC9555326
doi:
Banques de données
ClinicalTrials.gov
['NCT05414071']
Types de publication
Journal Article
Langues
eng
Pagination
e40317Informations de copyright
©Edward Meinert, Madison Milne-Ives, K Ray Chaudhuri, Tracey Harding, John Whipps, Susan Whipps, Camille Carroll. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 26.09.2022.
Références
Int J Neurosci. 2015;125(12):929-35
pubmed: 25387070
Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26
pubmed: 15230939
Urology. 2015 Jun;85(6):1304-10
pubmed: 25881867
Mov Disord. 2010 Apr 30;25(6):704-9
pubmed: 20437539
Parkinsonism Relat Disord. 2012 Jan;18(1):54-8
pubmed: 21917501
Transl Behav Med. 2017 Jun;7(2):254-267
pubmed: 27966189
Parkinsonism Relat Disord. 2012 Jun;18(5):483-7
pubmed: 22321866
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
Mov Disord. 2006 Jul;21(7):916-23
pubmed: 16547944
Front Psychol. 2020 May 27;11:926
pubmed: 32536888
J Med Internet Res. 2018 Nov 16;20(11):e292
pubmed: 30446482
JAMA Netw Open. 2020 Jul 1;3(7):e2010918
pubmed: 32678446
Lancet Neurol. 2018 Jun;17(6):559-568
pubmed: 29699914
Age Ageing. 1997 Sep;26(5):353-7
pubmed: 9351479
J Neurol Sci. 2007 Apr 15;255(1-2):77-80
pubmed: 17337275
Mov Disord. 2020 Jan;35(1):116-133
pubmed: 31571279
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Health Qual Life Outcomes. 2017 Aug 24;15(1):170
pubmed: 28838316
Acta Med Port. 2021 Jan 4;34(1):6-11
pubmed: 32716283
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Parkinsonism Relat Disord. 2007 Feb;13(1):22-8
pubmed: 16931104
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Mov Disord. 2009 Jan 30;24(2):183-7
pubmed: 18972545
Parkinsonism Relat Disord. 2004 Dec;10(8):493-9
pubmed: 15542010
J Med Internet Res. 2017 Nov 01;19(11):e367
pubmed: 29092808